Clinical bottom line
Low-dose naltrexone (LDN) is an emerging, putative adjunctive therapy for chronic inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease, that may modulate immune response and reduce inflammation. Preliminary clinical reports and small-scale studies suggest potential symptomatic improvement and mucosal healing in some patients, but robust, large-scale randomized controlled trials are lacking. LDN’s favorable safety profile and oral administration make it an attractive candidate for primary care consideration in refractory or mild-to-moderate IBD cases, though it currently remains an off-label, experimental approach warranting specialist collaboration and careful patient selection.
What the evidence shows
The therapeutic rationale for LDN in IBD centers on its hypothesized immunomodulatory effects via transient opioid receptor blockade, which may enhance endogenous endorphin release and downregulate pro-inflammatory cytokines. Kais et al. (2013) reported that LDN therapy improved clinical symptoms and endoscopic scores in patients with active ulcerative colitis, with a small cohort showing reduced disease activity after 12 weeks of treatment. Similarly, Shannon et al. (2010) described a pediatric case of duodenal Crohn’s disease where LDN led to clinical remission and mucosal healing, highlighting potential benefits beyond adult populations.
More recently, Glynn et al. (2026) synthesized emerging data on naltrexone’s role in IBD, underscoring its anti-inflammatory potential but emphasizing the limited size and heterogeneity of existing studies. These reports collectively suggest that LDN may reduce inflammatory markers and improve quality of life, though effect sizes and durability of response remain uncertain.
The safety profile of LDN appears favorable, with low incidence of adverse effects reported in IBD cohorts, consistent with its use in other inflammatory conditions (Case Medical Research, 2019). This contrasts with the known risks of prolonged corticosteroid use, which remains a common but problematic treatment in Crohn’s disease (Banks et al., 1997).
Caveats and uncertainty
Current evidence for LDN in IBD is largely derived from small, uncontrolled studies, case reports, and preliminary trials with limited follow-up duration. There is a paucity of large, randomized, placebo-controlled trials that definitively establish efficacy, optimal dosing, and long-term safety. The heterogeneity of IBD phenotypes and concomitant therapies complicates interpretation of outcomes.
Additionally, the mechanisms by which LDN may exert anti-inflammatory effects in IBD remain putative and incompletely understood. Biomarkers such as fecal calprotectin, useful in differentiating IBD from irritable bowel syndrome in primary care (Rouke et al., 2015), have not been systematically evaluated in LDN-treated patients to correlate clinical improvement with objective inflammation reduction.
Given these uncertainties, LDN should not replace established IBD therapies but may be considered as an adjunct in select patients, ideally within a multidisciplinary framework involving gastroenterology input. Clinicians should be cautious about off-label prescribing and ensure patients are informed about the experimental nature of LDN in this context.
How this may change practice
For general practitioners managing patients with mild-to-moderate IBD or those intolerant to conventional therapies, LDN represents a potential adjunctive option that may improve symptoms and reduce reliance on corticosteroids or immunosuppressants. Its oral administration and low side effect profile are practical advantages in primary care.
However, integration of LDN into routine practice requires further validation through rigorous clinical trials. Until then, GPs should consider LDN only after specialist consultation and in the context of shared decision-making, emphasizing its investigational status. Monitoring with clinical assessment and inflammatory markers remains essential to evaluate response and guide ongoing management.
Incorporating awareness of LDN’s emerging evidence may prompt clinicians to discuss novel therapeutic avenues with patients and specialists, potentially expanding individualized treatment strategies for chronic IBD.